Free Trial

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

+0.01 (+1.57%)
(As of 02:45 PM ET)
Today's Range
50-Day Range
52-Week Range
346,545 shs
Average Volume
934,313 shs
Market Capitalization
$40.72 million
P/E Ratio
Dividend Yield
Price Target

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Short Interest
3.00% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.67mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.28) to ($0.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

Medical Sector

800th out of 921 stocks

Biological Products, Except Diagnostic Industry

137th out of 154 stocks

BCLI stock logo

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Stock Price History

BCLI Stock News Headlines

Brainstorm Cell: Q4 Earnings Insights
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($0.08) per share


Free Float
Market Cap
$40.82 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Chaim Lebovits (Age 53)
    President & Co-CEO
    Comp: $878.78k
  • Dr. Irit Arbel DSc (Age 64)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Ms. Alla Patlis CPA (Age 37)
    M.B.A., Interim CFO & Controller
    Comp: $130.92k
  • Mr. Uri Yablonka (Age 47)
    Executive VP, Chief Business Officer, Secretary & Director
    Comp: $247.06k
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Senior Vice President of Patient Advocacy & Government Affairs
  • Dr. Ibrahim Dagher M.D. (Age 55)
    Executive VP & Chief Medical Officer

BCLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings
or view top-rated stocks.

How have BCLI shares performed in 2024?

Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI shares have increased by 123.4% and is now trading at $0.61.
View the best growth stocks for 2024 here

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our BCLI earnings forecast

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Kingswood Wealth Advisors LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCLI) was last updated on 5/23/2024 by Staff

From Our Partners